Top 5 Drug Type | Count |
---|---|
Small interfering RNA | 31 |
Oligonucleotide | 11 |
Chemical drugs | 1 |
Small molecule drug | 1 |
Target |
Mechanism TTR inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date13 Jun 2022 |
Target |
Mechanism ALAS1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date20 Nov 2019 |
Start Date05 Jun 2024 |
Sponsor / Collaborator |
Start Date17 May 2024 |
Sponsor / Collaborator |
Start Date25 Apr 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Vutrisiran ( TTR ) | Amyloidosis, Hereditary, Transthyretin-Related More | Approved |
Lumasiran sodium ( GOX ) | Primary Hyperoxaluria Type 1 More | Approved |
Givosiran Sodium ( ALAS1 ) | Porphyria, Acute Hepatic More | Approved |
Patisiran sodium ( TTR ) | Amyloidosis, Hereditary, Transthyretin-Related More | Approved |
Belcesiran ( A1AT ) | Alpha 1-Antitrypsin Deficiency More | Phase 2 |